(Q35148010)

6 August 2017

title

MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients (English)

1 reference

6 August 2017

0 references

0 references

Federico Serana

1

0 references

Claudio Gasperini

object named as

Claudio Gasperini

5

0 references

Maria Pia Amato

object named as

Maria Pia Amato

3

0 references

Giancarlo Comi

4

object named as

Giancarlo Comi

1 reference

6 August 2017

6

Angelo Ghezzi

1 reference

6 August 2017

15

Ruggero Capra

1 reference

6 August 2017

7

Vittorio Martinelli

1 reference

6 August 2017

13

Mauro Zaffaroni

1 reference

6 August 2017

8

Leandro Provinciali

1 reference

6 August 2017

11

Sergio Stecchi

1 reference

6 August 2017

Luisa Imberti

2

1 reference

6 August 2017

Maria Rosa Rottoli

9

1 reference

6 August 2017

Stefano Sotgiu

10

1 reference

6 August 2017

Michele Vecchio

12

1 reference

6 August 2017

Cinzia Cordioli

14

1 reference

6 August 2017

language of work or name

English

0 references

publication date

14 April 2014

1 reference

6 August 2017

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

e94794

1 reference

Creative Commons Attribution 4.0 International

6 August 2017

copyright license

start time

14 April 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Determinants of interferon β efficacy in patients with multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Predicting responders to therapies for multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Transfer of myxovirus-protein-A mRNA assay for interferon-β bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Modulation of IFNAR1 mRNA expression in multiple sclerosis patients

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Interferon receptor expression in multiple sclerosis patients.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Defining interferon beta response status in multiple sclerosis patients.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986392

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

27 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0094794

Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS

21 January 2018

1 reference

12 December 2020

Should we measure the bioavailability of interferon beta in vivo in patients with multiple sclerosis?

1 reference

12 December 2020

Predictive markers for response to interferon therapy in patients with multiple sclerosis

1 reference

12 December 2020

Neutralizing and Binding Antibodies to Interferon Beta in Patients with Multiple Sclerosis: A Comparison of Assay Results from Three Italian Centres

1 reference

12 December 2020

Anti-interferon-beta neutralising activity is not entirely mediated by antibodies

1 reference

12 December 2020

Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up

1 reference

12 December 2020

Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes

1 reference

12 December 2020

IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays

1 reference

12 December 2020

Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study

1 reference

12 December 2020

Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0094794

Identifiers

DOI

1 reference

6 August 2017

0 references

1 reference

6 August 2017

1 reference